How to buy Vivos Therapeutics stock

Vivos Therapeutics, Inc is a medical devices business based in the US. Vivos Therapeutics shares (VVOS) are listed on the NASDAQ and all prices are listed in US Dollars. Vivos Therapeutics employs 93 staff and has a trailing 12-month revenue of around USD$13.1 million.

How to buy shares in Vivos Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Vivos Therapeutics. Find the stock by name or ticker symbol: VVOS. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vivos Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vivos Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Vivos Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Vivos Therapeutics share price

Use our graph to track the performance of VVOS stocks over time.

Vivos Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-16.

52-week range	USD$5.64 - USD$14.41
50-day moving average	USD$7.5977
200-day moving average	USD$7.3874
Wall St. target price	USD$12
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	N/A

Buy Vivos Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vivos Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vivos Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vivos Therapeutics financials

Revenue TTM	USD$13.1 million
Gross profit TTM	USD$10.4 million
Return on assets TTM	-33.11%
Return on equity TTM	-157.7%
Profit margin	-92.28%
Book value	N/A
Market capitalisation	USD$152.1 million

TTM: trailing 12 months

Shorting Vivos Therapeutics shares

There are currently 41,931 Vivos Therapeutics shares held short by investors – that's known as Vivos Therapeutics's "short interest". This figure is 166.3% up from 15,747 last month.

There are a few different ways that this level of interest in shorting Vivos Therapeutics shares can be evaluated.

Vivos Therapeutics's "short interest ratio" (SIR)

Vivos Therapeutics's "short interest ratio" (SIR) is the quantity of Vivos Therapeutics shares currently shorted divided by the average quantity of Vivos Therapeutics shares traded daily (recently around 97513.953488372). Vivos Therapeutics's SIR currently stands at 0.43. In other words for every 100,000 Vivos Therapeutics shares traded daily on the market, roughly 430 shares are currently held short.

To gain some more context, you can compare Vivos Therapeutics's short interest ratio against those of similar companies.

• Alexion Pharmaceuticals (ALXN.US): 2.92
• HCA Healthcare (HCA.US): 1.76
• Gilead Sciences (GILD.US): 2.71
• Medtronic (MDT.US): 1.69

However Vivos Therapeutics's short interest can also be evaluated against the total number of Vivos Therapeutics shares, or, against the total number of tradable Vivos Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vivos Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Vivos Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0032% of the tradable shares (for every 100,000 tradable Vivos Therapeutics shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Vivos Therapeutics.

Find out more about how you can short Vivos Therapeutics stock.

Vivos Therapeutics share dividends

We're not expecting Vivos Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• HCA Healthcare (HCA.US) (0.23% forward annual dividend yield)
• Gilead Sciences (GILD.US) (4.17% forward annual dividend yield)
• Medtronic (MDT.US) (1.84% forward annual dividend yield)

Vivos Therapeutics overview

Vivos Therapeutics, Inc. , a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integrated Healthcare Network, provides access to healthcare providers for delivering care for patients suffering from sleep disordered breathing, including mild-to-moderate OSA. Vivos Therapeutics, Inc. also licenses its intellectual property to third-party manufacturers, which fabricate appliance devices for healthcare professionals.

Frequently asked questions

• What percentage of Vivos Therapeutics is owned by insiders or institutions?

  Currently 32.799% of Vivos Therapeutics shares are held by insiders and 4.08% by institutions.

• How many people work for Vivos Therapeutics?

  Latest data suggests 93 work at Vivos Therapeutics.

• When does the fiscal year end for Vivos Therapeutics?

  Vivos Therapeutics's fiscal year ends in December.

• Where is Vivos Therapeutics based?

  Vivos Therapeutics's address is: 9137 South Ridgeline Boulevard, Highlands Ranch, CO, United States, 80129